Book contents
- Frontmatter
- Contents
- List of illustrations
- List of tables
- Acknowledgements
- Introduction
- Part I Merchants and bonnie babies
- Part II Pharmaceuticals in Britain
- Part III Internationalisation of pharmaceuticals
- 10 Glaxo Laboratories and the international development of the pharmaceutical industry
- 11 Across the Atlantic: North and South America
- 12 The Commonwealth I: India and Pakistan
- 13 The Commonwealth II: Australia and New Zealand
- 14 The Commonwealth III: South Africa
- 15 Glaxo in Europe
- 16 Epilogue
- Appendix: Glaxo statistics
- Notes
- Select bibliography
- Index
16 - Epilogue
Published online by Cambridge University Press: 05 March 2012
- Frontmatter
- Contents
- List of illustrations
- List of tables
- Acknowledgements
- Introduction
- Part I Merchants and bonnie babies
- Part II Pharmaceuticals in Britain
- Part III Internationalisation of pharmaceuticals
- 10 Glaxo Laboratories and the international development of the pharmaceutical industry
- 11 Across the Atlantic: North and South America
- 12 The Commonwealth I: India and Pakistan
- 13 The Commonwealth II: Australia and New Zealand
- 14 The Commonwealth III: South Africa
- 15 Glaxo in Europe
- 16 Epilogue
- Appendix: Glaxo statistics
- Notes
- Select bibliography
- Index
Summary
The Glaxo Group in the early 1960s consisted of the business whose growth from its origins as a New Zealand merchanting firm has been traced in this history, along with the multifarious and only partially integrated activities of the companies with which it had merged in recent years. The acquisitions of Allen & Hanburys Ltd and Evans Medical Ltd were followed by those of the Edinburgh Pharmaceutical Industries Ltd in 1962, the British Drug Houses Group Ltd in 1967 and Farley's Infant Food Ltd in 1968. Over the next two decades rationalisation occurred, with the disposal of some subsidiaries involved in activities not related to the Group's primary objective, defined as the discovery, development, manufacture and marketing of prescription medicines.
From at least the time when Glaxo Laboratories became involved with penicillin, the company had identified itself as predominantly concerned with pharmaceuticals, but in 1962 about half of the value of home turnover was still derived from food products, dried milk, baby and infant foods. Over the next two decades Glaxo's strategy and structure changed and the Group's business expanded to a different level. While some expansion was a consolidation of existing operations, some was the result of changing the emphasis within the business and some came from new directions which the Group decided to follow, more particularly the decisions taken in the 1960s to introduce an international strategy and to start basic research.
- Type
- Chapter
- Information
- GlaxoA History to 1962, pp. 362 - 369Publisher: Cambridge University PressPrint publication year: 1992